JAG1 and neoplasm: Blocking the STAT3 activation by WP1066 effectively abrogated IL-6-induced Jagged-1 expression, strongly inhibited the growth of the trastuzumab resistant cells, and enhanced the anti-tumor activities of trastuzumab in the resistant cells.